What did Fisher & Paykel Healthcare Corporation Limited announce?
Fisher & Paykel Healthcare Corporation Limited (NZX: FPH) filed “2026 Annual Shareholders' Meeting Results” with NZX on 25 August 2026, as an agm announcement.
From the announcement:“Results of 2026 Annual Shareholders’ Meeting At Fisher & Paykel Healthcare Corporation Limited’s Annual Shareholders’ Meeting, held in Auckland and online today, shareholders were asked to vote on seven ordinary resolutions.”
- When was it filed?
- 25 August 2026
- Where is the original?
- NZX announcement
2026 Annual Shareholders' Meeting Results
News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)
25 August 2026
Results of 2026 Annual Shareholders’ Meeting
At Fisher & Paykel Healthcare Corporation Limited’s Annual Shareholders’ Meeting, held in Auckland
and online today, shareholders were asked to vote on seven ordinary resolutions. As required by NZX
Listing Rule 6.1, all voting was conducted by a poll.
The ordinary resolutions passed were:
Resolution 1: To elect Anna Curzon as a Director.
Resolution 2: To authorise the Directors to fix the fees and expenses of the auditor.
Resolution 3: To approve an increase to the maximum aggregate annual remuneration payable to
non-executive directors.
Resolution 4: To approve the grant of discretionary long term variable remuneration instruments to
Lewis Gradon.
Resolution 5: To approve the 2025 Performance Share Rights Plan – North America.
Resolution 6: To approve the 2025 Share Option Plan – North America.
Resolution 7: To approve the Employee Share Rights Plan – North America.
Details of the total number of votes cast in person, online or by a proxy holder are:
Resolution For Against Abstain
1: To elect Anna Curzon as a Director.
439,332,659
99.88%
514,296
0.12%
27,182
2: To authorise the Directors to fix the fees
and expenses of the auditor.
429,021,432
97.54%
10,823,333
2.46%
29,372
3: To approve an increase to the maximum
aggregate annual remuneration payable to
non-executive directors.
352,605,905
80.47%
85,601,037
19.53%
112,884
4: To approve the grant of discretionary
long term variable remuneration
instruments to Lewis Gradon.
429,735,033
97.98%
8,874,134
2.02%
706,131
5: To approve the 2025 Performance Share
Rights Plan – North America.
432,722,619
98.55%
6,386,217
1.45%
765,307
6: To approve the 2025 Share Option Plan
– North America.
431,054,743
98.16%
8,063,344
1.84%
756,056
7: To approve the Employee Share Rights
Plan – North America.
438,797,705
99.93%
326,148
0.07%
750,290
As at the commencement of the meeting, Fisher & Paykel Healthcare Corporation Limited had
587,302,790 total number of voting shares on issue.
Authority for this announcement
Name of person authorised to make this
announcement
Raelene Leonard
General Counsel & Company Secretary
Contact person for this announcement Raelene Leonard
Contact phone number +64 9 610 4803
Contact email address raelene.leonard@fphcare.co.nz
Date of release through MAP 25 August 2026
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems
for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The
company’s products are sold in over 120 countries worldwide. For more information, visit our website
www.fphcare.com.
Contacts
Media Investors
Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 21 713 911
Dan Adolph
Head of Investor Relations
daniel.adolph@fphcare.co.nz
+64 22 511 4050
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.